文献速递脑血管病

基因组风险评分识别脑出血高风险个体

A Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2023-02-17

结果显示metaGRS每增加1个标准差与脑出血风险升高31%相关,最高分位数个体风险约为对照的4.83倍,且在UK Biobank队列中与 incident 脑出血风险相关(HR 1.15)。

要点

  • metaGRS每增加1个标准差,脑出血风险升高31%(95% CI 1.16-1.48)。
  • 最高分位数个体脑出血风险约为对照的4.83倍(95% CI 1.56-21.2)。
  • UK Biobank中metaGRS与 incident 脑出血风险相关(HR 1.15,95% CI 1.09-1.21)。

核心结论

  • 研究开发并验证了一种基因组风险评分,可在已确立的临床风险因素之外预测欧洲血统个体的脑出血终身风险。
  • 作者认为,在高风险人群(如接受抗血栓治疗的患者)中将该评分纳入风险预测模型是否能改善临床决策,应在未来研究中探索。

研究设计与样本

  • 在包含842例病例和796例对照的独立验证数据集中测试metaGRS与脑出血的关联及预测效能。
  • 在基于人群的UK Biobank队列(486 784人,1526例事件,中位随访11.3年)中测试metaGRS与 incident 脑出血风险的关联。

主要发现

  • 在年龄、性别和临床风险因素校正模型中,metaGRS每增加1个标准差与脑出血风险升高31%相关(95% CI 1.16-1.48)。
  • 最高评分百分位个体脑出血风险约为对照的4.83倍(95% CI 1.56-21.2)。
  • 在临床预测因素基础上加入metaGRS的预测模型优于仅用临床风险因素的模型(c-index 0.695 vs 0.686)。
  • metaGRS对脑叶性和非脑叶性脑出血的关联相似,且独立于已知的脑叶性出血APOE风险位点。
  • 在UK Biobank中,metaGRS与 incident 脑出血风险相关(HR 1.15,95% CI 1.09-1.21),该关联在抗血栓药物使用的高风险人群和血管风险因素控制良好且未使用抗凝药的相对低风险人群中均显著。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者认为,在高风险人群中将该评分纳入风险预测模型能否改善临床决策,应在未来研究中探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intracerebral hemorrhage (ICH) has an estimated heritability of 29%. We developed a genomic risk score for ICH and determined its predictive power in comparison to standard clinical risk factors. METHODS: We combined genome-wide association data from individuals of European ancestry for ICH and related traits in a meta-genomic risk score ([metaGRS]; 2.6 million variants). We tested associations with ICH and its predictive performance in addition to clinical risk factors in a held-out validation dataset (842 cases and 796 controls). We tested associations with risk of incident ICH in the population-based UK Biobank cohort (486 784 individuals, 1526 events, median follow-up 11.3 years). RESULTS: One SD increment in the metaGRS was significantly associated with 31% higher odds for ICH (95% CI, 1.16-1.48) in age-, sex- and clinical risk factor-adjusted models. The metaGRS identified individuals with almost 5-fold higher odds for ICH in the top score percentile (odds ratio, 4.83 [95% CI, 1.56-21.2]). Predictive models for ICH incorporating the metaGRS in addition to clinical predictors showed superior performance compared to the clinical risk factors alone (c-index, 0.695 versus 0.686). The metaGRS showed similar associations for lobar and nonlobar ICH, independent of the known APOE risk locus for lobar ICH. In the UK Biobank, the metaGRS was associated with higher risk of incident ICH (hazard ratio, 1.15 [95% CI, 1.09-1.21]). The associations were significant within both a relatively high-risk population of antithrombotic medications users, as well as among a relatively low-risk population with a good control of vascular risk factors and no use of anticoagulants. CONCLUSIONS: We developed and validated a genomic risk score that predicts lifetime risk of ICH beyond established clinical risk factors among individuals of European ancestry. Whether implementation of the score in risk prognostication models for high-risk populations, such as patients under antithrombotic treatment, could improve clinical decision making should be explored in future studies.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Myserlis EP, Georgakis MK, Demel SL, et al. A Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage. Stroke. 2023. PMID: 36799223. doi:10.1161/STROKEAHA.122.041701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。